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Abstract
After reviewing currently available diagnostic assessment instruments for sub-
stance use disorders this paper describes the format and structure of the
Munich-Composite International Diagnostic Interview (M-CIDI) substance
disorder section. In addition, the test-retest reliability of diagnoses and criteria
for nicotine, alcohol, illegal and prescription drugs, is reported. Findings
obtained in community sample of adolescents and young adults indicate that
the substance section is acceptable for almost all types of respondents, efficient
in terms of time and ease of administration as well as reliable in terms of
consistency of findings over time. The test-retest reliability over a period of an
average of 1 month, as examined by two independent interviewers indicates
good-to-excellent kappa values for all substance disorders assessed, with sig-
nificant kappa values ranging between 0.55 for drug abuse and 0.83 for alcohol
abuse. There was also fairly consistently high agreement for the assessment of
single DSM-IV diagnostic criteria for abuse and dependence as well as the
M-CIDI quantity-frequency and time-related questions. To conclude, al-
though – unlike previous studies – this study was conducted in a community
sample and not in patients and used considerably longer time intervals of
more than a month between investigations, our M-CIDI reliability findings
are at least as high as those from previous studies.
OOOOOOOOOOOOOOOOOOOOOO
Introduction: The Need for Diagnostic
Assessment Tools for Substance Disorders
Although there has been a great deal of national and
international effort in the development of substance use
control policies (for alcohol, tobacco and other drugs), the
same has not been true until very recently for diagnostic
and classification instruments of substance use disorders.
Though a number of psychiatric instruments have been
developed for assessing the symptoms, the syndrome and
the impact of alcohol abuse and dependence, only very
few attempts have been made until recently to construct
similarly detailed tools for the assessment of drug use. At
the same time there is a great need for comparable ver-
sions of instruments that can be used in different settings,
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e.g. in the community, primary care, clinics, hospital set-
tings, psychiatric facilities and special substance abuse
programs for the following reasons: (1) The magnitude of
the problem should be assessed by epidemiological meth-
ods in general population surveys. It is also necessary to
assess ongoing changes and trends. There is, therefore, a
need for instruments to gather comparable data over
time. (2) Early detection is essential for the success of pre-
vention and intervention programs for the potential or
actual cases. Hence, there is a need for both efficient
screening and efficient diagnostic instruments. (3) Proper
assessment of cases is necessary for treatment, rehabilita-
tion and social reintegration purposes. Thus, instruments
are necessary for a better definition of patient types as
well as differential assessment of substance use disorder
in terms of etiology, presenting symptoms, abuse patterns,
substance-related problems and other associated features.
(4) Standardized instruments are necessary for compari-
son of symptom patterns across substances and also to
delineate the course and natural history of disorders.
(5) Diagnostic assessment instruments are also important
in the evaluation of the intervention programs in terms of
their process, outcome, cost-effectiveness, impact and ac-
ceptability.
To make a rational symptom and diagnostic assess-
ment of substance abuse, these instruments should gather
information on a large number of topics including both
current and lifetime substance use, primary substance
and secondary substance used, predominant route of ad-
ministration, amount used (dose), duration of use, pattern
of use, reason for initial use, treatment history and contact
with professional or other institutions, and problems
related to substance use. They should also include impor-
tant demographic, socioeconomic and criminal back-
ground data (e.g. ethnicity, family status, education, em-
ployment history, family history, sources of support) so
that multiple dimensions of the substance use problem
and the patient as a whole can be evaluated in relation to
the multiple dimensions of the substance use.
Development and standardization of assessment in-
struments to address these issues is a challenging task giv-
en the complexity of the problems (e.g. different sub-
stances, different diagnostic approaches, and cross-cultur-
al diversity of substance use). Fortunately, efforts to
create a ‘common language’ in the area of psychoactive
substance use has gained momentum in the last decade.
The World Health Organization (WHO) has revised
the International Classification of Disease creating its
tenth version [1a], parallel to a similar revision made to
the US-Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Revision [2]. Furthermore the WHO has
been carrying out a still ongoing joint project with the
former Alcohol, Drug Abuse, and Mental Health Admin-
istration of USA (ADAMHA) in which scientists and cli-
nicians all over the world have joined in a collaborative
effort to better define mental disorders. Within the frame-
work of this project two major diagnostic instruments
have been developed that are cross-culturally applicable
[1b, 3, 4] and that include substance use disorders [5].
With regard to the cross-cultural diversity of substance
use, standardized instruments have the potential to show
the similarities and differences across cultures which will
certainly improve our understanding of the biological,
psychological and social basis of these disorders.
A book that has recently been published by the Nation-
al Institute on Drug Abuse of USA (NIDA) [6] reviews the
different facets of the diagnostic assessment of substance
use disorders and strongly advocates using comparable
measures for evaluation. Babor [7], in his review of assess-
ment instruments, concludes that no single instrument
has yet been devised to suit the needs of different types
of users and suggests gathering data into three groups:
(1) variables reflecting lifetime involvement with alcohol
and drugs and global problem severity; (2) develop-
mental, etiological and substance use career variables,
and (3) variables related to the severity of presenting
symptoms and the nature and the pattern of substance
abuse. This chapter serves as an excellent guide for a clini-
cian or researcher who wants to create a customized
assessment battery for a study. It also indicates the mini-
mum of core variables necessary to link the data with oth-
er studies. Other helpful reviews have more recently been
provided by Freyberger and Stieglitz [8] and Günthner
and Stetter [9].
Diagnostic assessment forms the basis of epidemiologi-
cal as well as all treatment planning and other interven-
tions. As the problems of psychoactive substance use are
complex, a multidimensional assessment is suggested to
cover the use pattern, symptomatology, and consequences
of the substance use. This evidently time-consuming and
thus costly effort can be dealt with either within one com-
plex multifaceted assessment instrument or within a se-
quential process that begins with a time-efficient ‘screen-
ing’, proceeding to ‘assessment of problem’ and ends in a
‘personal in-depth assessment’ if needed [10]. This paper
will focus on the first of these approaches: two-stage pro-
cedures have been discussed elsewhere in more detail
[11].
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Currently Available Diagnostic Instruments
The advent of DSM-III and -IV and ICD-10 that use
specific sets of operational diagnostic criteria within the
framework of coherent classification systems has brought
a new perspective to instrument development. It is now
possible to translate these diagnostic criteria into ques-
tions and develop instruments for the assessment of psy-
choactive substance abuse. These instruments are useful
for the comprehensive assessment of problems, such as
level, pattern and history of use, and signs and symptoms
of psychoactive substance use, but they also allow the
objective derivation of diagnoses. There are different mo-
tives for the development of these instruments, especially
the fully structured ones such as the Composite Interna-
tional Diagnostic Interview (CIDI), the Diagnostic Inter-
view Schedule (DIS), and the CIDI-Substance Abuse Mo-
dule (SAM) that are developed for application by trained
non-clinicians rather than by clinicians. The following
interview schedules are indicative of the new generation
of diagnostic instruments developed for clinical assess-
ment and epidemiological research.
The WHO-Composite International Diagnostic
Interview and Derivations Thereof
The Composite International Diagnostic Interview
(WHO-CIDI, versions 1.0 to 1.2) is a fully structured
interview developed by the WHO [3]. It is a schedule pri-
marily intended for use in epidemiological studies of
mental disorders by trained nonclinicians, but it can also
be used for other research and clinical purposes. The
structure of the interview requires minimal judgement
from the interviewer, which ensures high levels of stan-
dardization and thus comparability of results. The core
version has alcohol and other drug use sections that can
produce ICD-10 and DSM-III-R diagnoses. The CIDI has
15 sections in modular format and can thus be tailored
according to the research questions and needs [4, 12]. The
reliability and validity of the core CIDI has been estab-
lished in various studies [13].
The CIDI was originally developed on the basis of the
Diagnostic Interview Schedule (DIS) by the National
Institute on Mental Health for the Epidemiological Catch-
ment Area Survey [12]. A major work has been published
by Helzer and Canino [14] that demonstrates what can be
achieved if standardized diagnostic instruments (DIS) are
used in research. The DIS has produced comparative data
from 10 different cultural regions that include American
Citizens including Native American and Puerto Rican
populations; French- and English-speaking Canadian
groups; a New Zealand population in the Pacific, and
three Asian populations in Taiwan, Korea and Shanghai
in China.
It also needs to be mentioned that several adaptations
of CIDI have been developed. The most frequently used is
the University of Michigan CIDI, that was used in a
National Institute on Mental Health-funded USA nation-
al survey of prevalence and comorbidity of alcohol, drug
and mental disorders [15] as well as in many more recent
studies around the world. The M-CIDI, discussed in more
detail below, is another such adaptation, necessary pri-
marily, because the official WHO CIDI version 2.0 that
will cover DSM-IV will not be available until the end of
1997.
Composite International Diagnostic Interview –
Substance Abuse Model
The CIDI-SAM [16] is a fully-structured extended
CIDI module that produces DSM-III, DSM-III-R, DSM-
IV Feighner, Research Diagnostic Criteria and ICD-10
diagnoses, and more recently proposed diagnostic vari-
ables for alcohol, tobacco and nine other drugs. It was
designed as an optional module to expand the substance
use sections of the CIDI. The diagnostic and item reliabil-
ities of this instrument were tested in a sample of more
than 900 patients in substance abuse treatment at four
sites in the USA for the field trials of DSM-IV and ICD-10
[5, 17, 18]. The work also provides information as to how
the criteria compare with each other. Very briefly CIDI-
SAM differs mainly from the standard CIDI in the follow-
ing ways: (1) substance-specific questions on medical,
psychological and social consequences are included; (2)
onset and recency of use are explored for each substance;
and (3) diagnostic coverage is expanded (e.g., heroin and
other opiates are evaluated).
Alcohol Use Disorders and Associated Disabilities
Interview Schedule
The Alcohol Use Disorders and Associated Disabilities
Interview Schedule (AUDADIS) was developed by the
USA National Institute on Alcohol Abuse and Alcoholism
[19]. It covers both the DSM and the ICD criteria for diag-
nosis and provides data for individual symptoms, symp-
tom scale scores, and the syndromal clustering of related
symptoms in time. It is currently being used in a large
international survey on biological markers of heavy alco-
hol consumption and in a longitudinal survey of sub-
stance use disorders and related psychiatric comorbidity
in the USA.
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Structured Clinical Interview for DSM-III-R and
DSM-IV
The Structured Clinical Interview for DSM-III-R
(SCID) [20] was developed by Spitzer and associates and
has recently been updated for DSM-IV. Here the examin-
er asks the suggested probe questions but is free to ask any
additional questions that he or she feels are necessary to
code the indicated DSM-III symptom. It has been widely
used in the USA [21–23], as well as some other countries
[4, 24] with demonstrated high reliability. However, for
some reason lower kappa values have been obtained for
the diagnostic subgroups [4]. This might be related to the
problems in reliably subtyping disorders or the differ-
ential diagnosis of affective disorders with psychotic dis-
orders. Currently, a more detailed version for alcohol and
drug use disorders SCID-A/D (Alcohol and Drug sections)
is being developed in parallel with AUDADIS with both
instruments sharing the same content and philosophy,
facilitating their comparison at the item level.
Schedules for Clinical Assessment in Neuropsychiatry
The Schedules for Clinical Assessment in Neuropsy-
chiatry (SCAN) are a set of instruments developed by the
WHO [1b] aimed at assessing, measuring and classifying
the psychopathology and behavior associated with the
major psychiatric disorders of adult life. SCAN is in-
tended for use by clinicians as a comprehensive set of
schedules to collect clinicial information. The system is
based on the well-known Present State Examination sys-
tem with the recent addition of alcohol and other drug
sections. The interview uses the clinical ‘cross-examina-
tion’ that explores the presence of predefined symptoms.
There is an accompanying glossary that gives the defini-
tions for each symptom and thus forms the core of the
system. The SCAN system also has a syndrome checklist,
the ‘Item Group Checklist’ as well as ‘Clinical History
Schedule’. For most symptoms some probes are recom-
mended, although the interviewer is free to ask any ques-
tions to assess the presence and severity of the symptom.
It is a symptom-based diagnostic tool where rules for
ICD-10 and DSM-IV classifications are tailored to the
computer programs (CATEGO) and hence it is relatively
immune to changes in the diagnostic classification. The
system includes a computer-assisted interview, computer-
ized scoring programs and a training package [25]. It is
important to note that CIDI and SCAN are comprehen-
sive instruments covering other aspects of mental func-
tioning and also tobacco use. To our knowledge no stan-
dardized ICD-10 and DSM-III-R tobacco dependence
assessment schedules other than CIDI and SCAN exist.
They may, therefore, shed light on the conceptual and
methodological considerations for tobacco dependence
research [26].
Checklists for Diagnostic Criteria and Symptoms
There are also ICD-10 and DSM-III-R checklists that
directly assess whether the criteria sets of these systems
are fulfilled. These replicate the operational diagnostic
criteria as stated in the classification systems [27] and
require the clinician to rate whether these are present.
However, without extensive prior training the test-retest
reliability of these instruments across centers is usually
lower and the symptoms and patterns-of-use documenta-
tion usually lacks the necessary detail.
Common Features of Diagnostic Instruments
Several comments should be made concerning the
common features of these diagnostic instruments:
(1) As Robins [28] points out, these instruments collect
and record data in the smallest units possible and put all
the elements of the major current diagnostic systems into
a single instrument. This ‘atomic’ and ‘multi-diagnostic’
approach permits data to be analyzed for multiple pur-
poses and may be useful following the future revisions of
the classification systems.
(2) Almost all the screening and assessment instru-
ments, except the WHO/ADAMHA instruments, have
been developed into one culture, for a particular diagnos-
tic tradition, and then introduced to other cultures. It is
questionable, however, whether they really do capture all
the relevant aspects of substance use as it occurs in differ-
ent cultures. It is important to note that CIDI and SCAN
have been developed as a result of a collaborative effort of
a network of centers all over the world designed for use in
different cultural settings. Translations exist in more than
15 languages and the WHO is currently undertaking a sys-
tematic study on the cross-cultural applicability of the
alcohol and drug use sections of these instruments [Cotter
et al., pers. commun.; to be published in Drug Alcohol
Depend]. This project employs a multidisciplinary ap-
proach that integrates different methods from various
social sciences (sociology, anthropology, ethnography, lin-
guistics and psychology). This endeavor will help the stan-
dardization of instruments in a culturally meaningful way
and hopefully improve our understanding of cultural
specificity.
(3) Another critical issue for all these instruments is
that, because of the lack of a sound database, they use dif-
ferent thresholds with regard to the quantity and frequen-
cy of the use of the substance. Some research has been
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devoted to this problem with regard to the so-called stan-
dard drink [29], but there is little data available for other
substances.
(4) With the advent of official classification systems
with precise diagnostic criteria we can now make better
measurements of psychopathological conditions. How-
ever, the validity of a diagnostic category, and thus the
validity of diagnostic instruments still remains question-
able as we lack the evidence of specific diagnostic stan-
dards in substance use disorders. Therefore, what is mea-
sured by the diagnostic instrument has to be verified not
only by clinical description and delimitation from other
disorders [21], but also by laboratory and family studies,
and studies on course and outcome (e.g. treatment re-
ponse). It is, therefore, important to collect data on the
predictive validity of both the diagnostic concepts and the
instruments.
(5) As the comprehensive assessment of an individual
case is more than the derivation of a simple diagnosis,
additional instruments have been developed to cover the
areas of social and environmental factors related to sub-
stance use for the differential and multi-axial assessment
of patients in clinical settings. These include detailed indi-
vidual assessment of the case on: (1) symptoms and pat-
terns of use including quantity and frequency; (2) prob-
lems caused by substance use; (3) familial, social and envi-
ronmental influences, such as severity of the condition
and disability, and other consequences of use in a more
comprehensive evaluation process. An example of this
type of approach is the Europ ASI (Addiction Severity
Index) [review by Kokkevi and Hartgers, 30].
(6) In the context of comprehensive assessment it is
also worthwhile to note that currently available laboratory
markers of alcohol consumption (e.g. gamma-glutamyl
transferase, mean cell volume, uric acid and high-density-
lipoprotein cholesterol) are fairly insensitive, although
when abnormal would certainly contribute to the diagno-
sis of harmful alcohol consumption. Laboratory tests for
other drug use are limited basically to measuring the drug
or its metabolites or both in blood or other body fluids. All
they indicate is whether the person has taken that particu-
lar substance recently, with the time-frame depending on
the half-life of the drug. For the long-term physical effects
of the substances (e.g. on the brain, liver or other organs
and systems) there is a wide range of markers to be exam-
ined to assess the harmful consequences of substance use.
(7) Finally, it should also be mentioned that compre-
hensive assessment instruments should also allow the
evaluation of the ‘neurocognitive status’ of the respondent
[31, 32] to ascertain the validity of the responses.
The Munich-CIDI Substance Sections –
Format, Structure and Content
The remainder of this article will now be devoted to the
M-CIDI sections for substance disorders. Because we
have described the overall format of this instrument
together with its background elsewhere in this issue
[Wittchen et al., p. 18; 33, 35], this discussion will be lim-
ited to special features of the substance sections as well as
its reliability.
General Features
The Munich Composite International Diagnostic In-
terview (M-CIDI, version 2.0) substance sections are
available in a lifetime and a 12-month version in various
languages [33]. Both versions should be administered
using a computer, with the interviewer reading each ques-
tion and subsequently entering the response or for some
questions verbatim responses directly into the computer.
A paper/pencil version is also available requiring, how-
ever, more training and of course subsequent entry into
the computer, making paper-pencil administration more
vulnerable to mistakes and errors as well as less time effi-
cient.
The M-CIDI includes three separate sections for the
assessment of substance disorders, namely for nicotine
dependence, alcohol abuse and dependence as well as for
drug and prescription abuse and dependence. All three
modules are, consistent with the standard WHO-CIDI,
fully standardized and have three parts:
Part A contains screening questions to evaluate first
use, frequency and quantity of use of each type of sub-
stances; these questions are put to everybody. Unlike the
standard CIDI, various questions were added to evaluate
circumstances of first use, effects, and problems associat-
ed with the initiation of drug use as well as more quantita-
tive information about the type of drug and its amount.
Part B evaluates the DSM-IV and ICD-10 diagnostic
criteria for each type of substance. The evaluation of some
diagnostic criteria requires several questions or the pre-
sentation of a respondent list, to make it easier for the
respondent to give reliable answers. The M-CIDI diagnos-
tic questions are administered to all subjects who ac-
knowledge at least repeated use of the respective sub-
stance assessed. These questions are identical to those in
the standard CIDI. For nicotine and alcohol as well as for
some criteria in the substance section age-of-onset and
recency questions were not added directly after each crite-
ria question, but at the end of the section as part of the
summary evaluation in Part C. Another special feature of
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Table 1. Examples from the CIDI
substance sections Example 1:
Nicotine section
Aim is to assess criterion
A(2) of DSM-IV
(‘withdrawal’)
M-CIDI question B16
I am going to ask you about several problems you might have had
in the first few days after you quit or cut down smoking. Please
look at list B1 (contains 12 withdrawal symptoms A–O). Which
of these difficulties on the list did you have when you quit or cut
down smoking? You can simply tell me the letters.
LETTERS ARE CODED!
Question B17:
A. Did you ever start using tobacco again, to avoid or to keep
from having any of these problems caused by quitting or cut-
ting down?
B. And how much did these difficulties upset you or affect your
everyday life?
Example 2:
Drug section
Aim is to assess DSM-IV
criterion (3)
Question L13
A. Have there ever been times when you used more (insert each
qualifying substance, for example cannabis) than you in-
tended to?
B. Or did you use (substance) for much longer periods than you
intended to?
C. And when was the first time you (repeat italicized part of
question!)?
D. And when was the last time you (repeat italicized part of
question!)?
Example 3:
Summary question in
alcohol section
Aim is to ascertain
12-month clustering of
diagnostic symptoms
Question I19
Please look at list I4. Here all the questions we just discussed are
briefly summarized. I’ll summarize again what you have told me;
you said you (all acknowledged symptoms evaluating the diagno-
stic criteria are repeated)... Did any of these difficulties and
things ever happen at about the same time, that is within a 12-
month period?
A. Which of the things from the list happened first? Which last...
etc.
B. And when did they happen first (code time and age) and
when for the last time? (code)
the M-CIDI is that the abuse questions are separated from
the dependence questions, because some respondents find
these questions offensive and might change their response
pattern as a consequence. Furthermore, critical questions
pertaining to problems with the police, arrests and legal
consequences are asked as part of a visual aid in order to
make sure that these critical questions and especially their
answers cannot not be heard by any other person who
might be listening to the interview.
Part C consists of a series of questions meant to assess
whether the acknowledged events ever occurred together,
that is in any 12-month period in the respondent’s life,
and, further, when the acknowledged criteria were first
and last met.
Table 1 gives examples for different types of questions
from each of these three parts and also clarifies how the
the M-CIDI translates diagnostic criteria into specific
questions.
When comparing the M-CIDI with the standard CIDI
the following modifications need to be mentioned: (1) a
more detailed quantity and frequency section; (2) the sep-
aration of time-related information about onset and re-
cency into a separate series of questions at the end, and
(3) the extensive use of visual aids to identify substances
properly to help in the presentation of complex questions
as well as to avoid asking potentially embarrassing ques-
tions out loud. Furthermore, the M-CIDI includes the
option of the administration of a health belief question-
naire, assessing motivations to use, knowledge about the
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Table 2. The response card with standard drink translation
risks of using the substance, the motivation for changing
the patterns of use, or stopping, and subjective as well as
objective barriers to potential changes.
Structure and Special Features of the Nicotine Section
This section allows for the assessment of lifetime and
current use of nicotine (cigarettes, cigars, pipes, tobacco
chewing or sniffing), along with information about the
presence and absence of each DSM-IV and ICD-10 de-
pendence criterion, dependence diagnosis and course
over time. Part A: Whenever the respondent acknowl-
edges the use of at least one of the above, 11 questions
about the age and circumstances of first use, amount and
various forms of reactions and effects are asked. These
questions are followed by series of quantity and frequency
questions along with information about onset and recency
of regular use as well as questions about current and peak
use for the the amount of cigarettes and their type. Part B
is only asked to respondents who have used nicotine at
least once daily over a period of at least 4 weeks, and con-
sists of 12 symptom questions designed to evaluate the
dependence criteria. Complex criteria, such as those for
tolerance, withdrawal and physical as well as psychologi-
cal problems related to the use are broken down into sev-
eral stepwise questions or are supported by a visual aid in
which the critical elements of the respective questions are
represented. Whenever at least one symptom (diagnostic
criterion) is acknowledged, onset and recency is evaluated
in part C and coded accordingly into the computer. It
should be noted, however, that only up to three core diag-
nostic criteria are dated in detail. The DSM-IV and ICD-
10 clustering criterion is assessed in two alternative ways:
either the respondent acknowledges having had at least
three criteria within a twelve-month period, or the age of
onset and recency information collected directly allows
the interviewer to decide this criterion.
Structure and Special Features of the Alcohol Section
As in the nicotine section this section allows the assess-
ment of lifetime and current use of alcohol along with
information about the presence and absence of each
DSM-IV and ICD-10 abuse and dependence criteria,
diagnosis and course over time. Part A: Whenever the
respondent acknowledges the use of at least one drink of
alcohol, 11 questions about the age of first use, circum-
stances of first use, amount and various forms of reactions
and effects are asked. These questions are followed by
series of quantity and frequency questions along with
information about onset and recency of regular use as well
as questions about current and peak use for the amount
and type of alcohol. In addition to the features that are
identical to the nicotine section, this screen is supported
by a visual aid summarizing the most prevalent types of
locally available alcoholic beverages with information
about their alcohol content. Throughout the subsequent
assessment the M-CIDI uses the concept of the standard
drink as shown in table 2 that has been adapted to local
types of beverage consumption. In addition, special probe
questions are used for those respondents who say they
never drink any alcohol to make sure that they also take
into account beer or wine consumed at a meal or fes-
tivity.
Part B is only asked to respondents who have used
alcohol at least 12 times within any one year period of
their life. These respondents are then asked for the exact
quantity and frequency by using the standard drink defi-
nition on their response card, which can be subsequently
translated by the diagnostic program into grams of alcohol
per week, month, and year and over the past 12 months as
well over a lifetime. Peak and current episodes of drinking
behavior is also evaluated. Because it is extremely unlike-
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Table 3. Summary characteristics for
the drug and prescription drug section Substances assessed Special features
1 Cannabinoids For each specific substance:
2 XTC and related substances – Assessment of mode of administration
3 Other stimulants – Frequency (one time only/2–4 times/5 and more)
4 Prescription stimulants – Frequency and duration if 5 times or more
5 Sedatives/hypnot./anxiolytics – First use and initial stage appraisal for all users
6 Prescribed sed./hyp./anx. – Assessment of all dependence criteria
7 Opioids – Assessment of age criteria were first and last met
8 Prescribed opioids – Additional probes for frequency of criteria
9 Cocaine/crack – Use of coded respondent lists for withdrawal and
10 PCP – Separately for physical and psychological problems
11 Psychodelics/hallucinogens – Use of summary dependence criteria list to
12 Inhalants/solvents summarize
13 Other, specify – Separate assessment of abuse criteria
– Separate list for police, legal and criminal acts
ly that persons in our culture without a lifetime weekly
consumption of 1–24 g absolute alcohol (equal to 3 stan-
dard drinks) and who, at the same time, never drink alco-
hol on more than two occasions per week, develop any
abuse or dependence criterion, no further diagnostic ques-
tioning is pursued with these subjects.
All remaining subjects are subsequently questioned
using a similar formulation to that in the nicotine section
for the presence or absence of dependence criteria. In
addition, response lists similar to those in the nicotine sec-
tion are used. Whenever at least one dependence criterion
is acknowledged, age-of-onset and recency is coded, sup-
ported by a summary statement and a response list to
assess the clustering criterion. Unlike the standard WHO-
CIDI, however, all eight abuse questions are asked and
dated separately after the dependence portion. Possibly
embarrassing questions can be assessed by use of a
response list to avoid answering out loud.
Structure and Special Features of the Prescription and
Illegal Drug Section
This section is designed to evaluate both symptoms
and syndromes of DSM-IV and ICD-10 categories of
abuse and dependence of illegal and legal psychotropic
substances, such as prescription drugs. Table 3 summa-
rizes the type of substances assessed with the variables
evaluated for each of these.
The screening part of the M-CIDI drug section (part A)
starts with the assessment of prescription drugs, either
prescribed or taken on their own. Supported by a complex
response list, various specific types of sedating, stimulat-
ing, or other drugs with a psychotropic potential are pre-
sented using their market names. Whenever the respon-
dent acknowledges having used any type of these sub-
stances on more than 5 occasions either on its own, or in
amounts greater or over longer periods than prescribed,
the subsequent part B questions along with questions
about quantity, frequency and onset, recency and dura-
tion are asked. Questions about the use of illegal drugs are
introduced by a commitment probe, in which the person
is asked whether he or she is willing to respond to these
questions openly. If this is denied, the complete section is
left out.
Consistent with the standard WHO-CIDI the respon-
dent has to acknowledge having used the respective drug
on at least five occasions to qualify for the subsequent
quantity, frequency, onset, recency and duration ques-
tions as well as the diagnostic criteria questions. Further
questions ask for mode and route of administration as
well as age, circumstances, and effects of first and initial
stages of the substance use. As in the alcohol section,
abuse questions are grouped at the end of the dependence
section in a separate module along with criterion-specific
questions of onset and recency of the abuse symptoms.
The drug section is especially complex and difficult to
administer by paper and pencil, if the respondent has
acknowledged the use of more than one substance more
than five times. The use of the computerized version
shortens administration time tremendously and reduces
potential errors of administration considerably. Diagnos-
tic questions in part B are asked for every single type of
substance, along with probe questions and onset and
recency information.
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What Is the Reliability of the M-CIDI Sections?
Most of the M-CIDI substance questions as well as the
algorithms of the M-CIDI have already been studied in
various studies prior to the development of our additional
modifications. However, only a few studies have exam-
ined how the CIDI works in 14- to 24-year-olds and even
fewer have used community samples. Thus we decided to
primarily investigate the reliability and validity in a com-
munity sample of young respondents and to focus particu-
larly on an assessment of our modifications and addi-
tions. In this section we will first present findings from
previous studies before reporting the findings of a test-
retest study of 60 community subjects.
Previous Studies
A systematic review of several available test-retest and
interrater reliability studies of the CIDI substance sec-
tions [13] demonstrated that substance use disorders are
among the most consistent and reliable diagnostic sec-
tions covered by this instrument. Interrater reliability was
found to be almost perfect in a large cross-national study
(n = 575), with test-retest findings ranging between kappa
values of 0.73 (illegal drugs), 0.79 for tobacco and 0.78 for
alcohol use disorders [13]. Further studies also ascer-
tained high acceptability and feasibility [5]. With these
findings in mind we were now interested to see whether
the M-CIDI produced similarly satisfactory high coeffi-
cients in young adults from the community.
M-CIDI Test-Retest Reliability Study
Methods. The basic design of this study is almost iden-
tical to previous reliability studies conducted with the
CIDI [34] to allow for direct comparisons with previous
findings: Respondents, after having had a preliminary
CIDI interview, were invited for a second independent
identical CIDI interview by a different interviewer, not
knowing the findings of the first interview. Subjects were
informed that the two interviews were not a memory test,
but part of a methodological investigation in order to
examine how well the interview worked. Further, they
were informed that the retest interviewer was blind to the
findings of the first interview, and thus, they should
answer to the best of their knowledge and judgement in
the particular assessment, not assuming that symptoms
indicated in the test interview did not need to be reported
again in the retest interview. Given the difficulties in
recruiting cases from the community at two occassions, it
was not feasible to have the short test-retest intervals of
1–3 days as in most previous studies. The mean time
interval between investigations in our study was 38.5 days
(SD: 53.7), ranging from 7 to a maximum of 112 days.
Table 4 summarizes the average and range of time inter-
vals between the test and the retest interviews along with
information about the 60 participants in the study.
All subjects were sampled from respondents participat-
ing in the baseline investigation of a longitudinal 5-year
study on prevalence, risk factors and incidence of mental
disorders in a representative sample of 3,021 community
residents in the greater Munich area, aged 14–24 years at
the time of the interview [35]. After completion of the
baseline interview (= test interview), each incoming inter-
view was checked by the survey administrator for the
number of symptoms in each diagnostic section. For the
retest interview only subjects with at least one symptom
in anyone of the M-CIDI sections were approached, in
order to avoid a high proportion of definite noncases that
could artificially inflate diagnostic concordance rates as
well as to increase the number of cases with at least one
diagnosis. To ensure sufficiently high symptomatic base
rates, the survey administrator made sure in his selection
of incoming consecutive interviews, that at least 5 cases
were represented in each major CIDI section. In his selec-
tion process he first started with recruiting subjects with
positive symptom questions in the nicotine section, and
Table 4. Design, respondents, interview and interviewer charac-
teristics
Time interval between test and retest (n = 60)
Average length (days): mean (SD) 38.5 (53.7)
Number (%) short interval (!4 weeks) 40 (67.8%)
Number (%) long interval (14 weeks) 20 (32.2%)
Respondents (n = 60)
Females 42 (70.0%)
Males 18 (30.0%)
Mean age (SD) 22.8 (8.1)
Still in school/education 24 (40.0%)
Employed 17 (28.3%)
Other (hoursewife, unemployed) 19 (31.7%)
Married 7 (11.7%)
Single 51 (85.0%)
Other 3 (3.3%)
Interview duration, min
Nicotine (mean (SD) and range) 3.6 (5.1) (0.2–19.4)
Alcohol (mean (SD) and range) 7.6 (5.3) (0.3–18.9)
Drugs (mean (SD) and range) 5.1 (5.8) (0.4–32.6)
U59:ZEUAR130XA SIBY
Structure, Content and Reliability of the
M-CIDI
Eur Addict Res 1988;4:28–41 37
subsequently added respondents with somatoform, anxi-
ety, affective, eating disorder, alcohol, other substance
disorder symptoms. Financial and personal resources
only allowed the examination of 60 cases, all of whom
agreed to participate.
24 interviewers, 16 women and 8 men, conducted at
least 4 of the 120 test and retest interviews. The mean age
of interviewers was 28.4 years (range 21–47 years). Four-
teen of them were psychologists in postgraduate training
in clinical psychology, six were students and four were
professional health survey interviewers with various non-
clinical backgrounds. All had significant experience in
both the paper and pencil as well as the computerized ver-
sion from participating in at least two separate 4-day
training sessions using the M-CIDI and had completed at
least five interviews in the field under the supervision of
an experienced CIDI user.
Analysis. Diagnostic concordance was calculated by
using the kappa statistics, additionally Yules Y coefficient
and percentage agreement is indicated, along with a cross-
tabulation of the raw data. Agreement for continuous
variables is measured with the intra-class coefficient
(ICC).
Results
Duration and Acceptance
In accordance with previous experience from the
above-mentioned method studies, all respondents found
the interview highly acceptable and had no complaints
about length. The overall length of the complete M-CIDI
is about 75 min, with the three substance sections taking
together on average about 16.3 min (table 4) in our com-
munity cases. The alcohol section with an average 7.6 min
was the longest. The range, however, was considerable
with the longest interview taking 32.6 min for the drug
section alone. The longest administration time observed
for alcohol and nicotine was 18.9 and 19.4 min, respec-
tively.
Diagnostic Agreement
Table 5 summarizes the kappa and Yules Y agreement
coefficients with their significance level together with a
cross-tabulation. Although base rates are low especially
for drug disorders, diagnostic agreement in terms of kap-
pa were found to be all significant and good for nicotine
(Î = 0.64), acceptable for drug abuse (Î = 0.55) and excel-
lent for alcohol use disorders. The Yules Y values, which
are less sensitive to low base rates are consistently higher.
The examination of disagreement reveals a slightly higher
DSM-IV diagnosis Cross-tabulation % agreement kappa (Yules Y)
Nicotine dependence T-n T-y 90.0 0.64** (0.73)
RT-n 47 2
RT-y 4 7
Any alcohol disorder T-n T-y 93.3 0.78*** (0.82)
RT-n 47 2
RT-y 2 9
Alcohol abuse T-n T-y 95.0% 0.83*** (0.87)
RT-n 48 1
RT-y 2 9
Any drug disorder T-n T-y 95.0% 0.64*** (0.80)
RT-n 54 1
RT-y 2 3
Drug abuse T-n T-y 95.0% 0.55* (0.76)
RT-n 55 1
RT-y 2 2
* p ! 0.05; ** p ! 0.01; *** p ! 0.001.
Table 5. Diagnostic test (T)-retest (RT)
reliability (base rates, kappa, percentage) of
DSM-IV diagnoses of abuse and
dependence of substances
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Table 6. Test (T)-retest (RT) reliability (base rates, kappa, percentage) of DSM-IV diagnostic criteria for abuse
and dependence
DSM-IV diagnostic criteria Cross-tabulation % agreement kappa (Yules Y)
I. Abuse criteria
A1: Failure in major role obligations T-n T-y 96.8 0.49 (0.60)
RT-n 57 0
RT-y 2 1
A2: Recurrent use in hazardous situations T-n T-y 93.3 0.79*** (0.83)
RT-n 46 2
RT-y 2 10
A3: Recurrent legal problems no sufficient base rate
A4: Continued use despite persistent social T-n T-y 98.3 0.85*** (0.85)
problems RT-n 56 1
RT-y 0 3
II. Dependence criteria
1 Tolerance T-n T-y 85.0 0.59*** (0.65)
RT-n 41 6
RT-y 3 10
2 Withdrawal T-n T-y 90.0 0.69*** (0.74)
RT-n 46 2
RT-y 4 8
3 Compulsive use T-n T-y 86.7 0.67*** (0.71)
RT-n 39 5
RT-y 3 13
4 Unsuccessful desire to stop/cut down/control T-n T-y 86.7 0.69*** (0.72)
RT-n 37 5
RT-y 3 15
5 Great deal of time using and recovering T-n T-y 88.3 0.57** (0.63)
from drug RT-n 49 2
RT-y 2 7
6 Narrowing of repertoire T-n T-y 90.0 0.52** (0.67)
RT-n 50 2
RT-y 4 4
7 Continued use despite physical/psychological T-n T-y 88.3 0.68*** (0.72)
problems RT-n 42 3
RT-y 4 11
** p ! 0.01; *** p ! 0.001.
number of cases found by the retest interviewer, except
for alcohol disorders.
Agreement on Diagnostic Criteria
Table 6 summarizes the agreement with regard to the
assessment of each DSM-IV criterion for abuse and
dependence across the three types of substances assessed.
In interpreting the abuse criteria one should consider first
that there is no diagnosis of abuse of nicotine and, sec-
ondly, that the base rates for criteria A3 and A1 are too
low for a meaningful interpretation. The most frequently
mentioned abuse criterion is the recurrent or persistent
use of the substance in hazardous situations with an
almost excellent kappa coefficient of 0.79 and few dis-
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Table 7. Agreement of quantity-
frequency questions as well as onset and
recency information in the substance
section; intra-class coefficients
Variable n ICC MSB MSW F value
Number of cigarettes smoked 32 0.880 166.1 10.6 15.7
Amount of alcohol consumed (standard drink) 50 0.947 38.2 1.1 1.8
Age of first nicotine use 48 0.834 2.9 0.27 11.0
Age of first alcohol use 20 0.964 99.6 1.8 55.3
Age of first illicit drug use 10 1.00 543.1 0.10 5431.0
ICC = Intra-class coefficient; MSB = mean square between subjects; MSW = mean
square within subjects.
crepancies. Abuse criterion A4 (continued use, despite
persistent problems) shows only one discrepant case and a
kappa of 0.79; however, the base rate of 4 cases is quite
low. Among dependence criteria ‘unsuccessful efforts to
cut down on use’ (4), compulsive use (3) and tolerance (1)
were the most frequently acknowledged criteria. All kap-
pa values are significant and range between a low of kappa
of 0.52 for narrowing of repertoire and a high of kappa of
0.69 for withdrawal syndrome and cutting down. A closer
exploration of substance-specific discrepancies reveals,
with one exception, no interpretable differences for type
of substance. However, most of the discrepancies in crite-
rion 6 (narrowing of repertoire) can be found among nico-
tine users.
Agreement on Quantity and Frequency as well as
Time-Related Questions
Taking the ICC as a yardstick (table 7), there is excel-
lent agreement both in terms of quantity-frequency esti-
mations made in the test and retest interview, as well as
age-of-onset rating for substance use. In addition, agree-
ment for the M-CIDI distinction of subjects who have just
tried the substance once, repeated use (2–4 times) and reg-
ular use (more than 4 times), reveals high agreement coef-
ficients; the resulting weighted kappa is highly significant
(Î = 0.72).
Discussion
With this paper we have provided a detailed overview
of the M-CIDI’s substance sections format, structure and
content, supplementing a more detailed presentation of
the M-CIDI overall reliability in a different paper [35].
Although many, especially criteria-based questions of this
instrument are identical with those in the standard CIDI,
our modifications have improved the flow and the ease of
administration considerably by, for example, more exten-
sive use of response lists as well as the separation of
dependence and abuse questions. The M-CIDI also offers
various additions, especially tailored to research in the
field of adolescent and young adult substance abuse.
Among these, the module for assessing variables related to
the initiation of substance use may prove to be very help-
ful. Compared to the administration times for the paper
and pencil version, the average administration time has
been significantly reduced for the substance sections by
about 20% [13]. This may be due to the computerized
administration as well as the more frequent use of respon-
dents lists. Although initially we had several concerns
about the use of laptop interviewers for such diagnostic
purposes, no respondent investigated objected to the com-
puterized administration with an interviewer reading the
questions from the screen.
In terms of the psychometric properties we first need to
acknowledge several limitations. First the base rates for
the test-retest examination was fairly low, not allowing us
to examine all M-CIDI questions in detail. Furthermore,
the same limitation did not allow us to trace back in detail
why discrepancies between the two administrations had
occurred. Thirdly, we studied the reliability in a fairly
young community sample. This is an advance compared
to previous studies that had examined reliability primari-
ly in identified patient samples. At the same time we need
to acknowledge that we had only a few severely ill subjects
with a substance disorder. Thus our findings should be
generalized to community cases not to patient popula-
tions, where we might expect slightly different findings.
In summary our reliability findings obtained in a ran-
dom community sample of 60 adolescents and young adults
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indicate that the substance section is acceptable for almost
all types of respondents, efficient in terms of time and ease
of administration as well as reliable in terms of consistency
of findings over time periods of at least a month. The test-
retest reliability over a period of an average of one month,
as examined by using two independent interviewers indi-
cates good to excellent kappa values for all substance disor-
ders assessed, with significant kappa values ranging be-
tween 0.55 for drug abuse and 0.83 for alcohol abuse. There
was also fairly consistently high, though slightly lower
agreement for the assessment of single DSM-IV diagnostic
criteria for abuse and dependence. These test-retest find-
ings compare well with, or are even better than, most pre-
vious studies using a similar design with shorter time inter-
vals [13], both with regard to diagnosis as well as to the
onset and quantity-frequency questions [36].
To conclude, although this test-retest – unlike to pre-
vious studies – was conducted in a community sample
and not patients and used a considerably longer time
interval of more than a month between investigations, our
findings demonstrate that the CIDI substance use sections
produce fairly consistent diagnostic and symptom data
over a period of at least a month, even if many different
trained interviewers are involved.
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